Search
Differential exposure and effect of malaria results from blends of biophysical, geospatial, and social determinants of health (SDoH). Likewise, effective policies and programmatic interventions against malaria must consider the complex interaction of social and spatial factors, while comprehensive health promotion approaches must simultaneously tackle SDoH and the ecological dimensions that drive malaria.
Immunisation is the most effective way of protecting your child against a range of serious illnesses, including measles, hepatitis B and whooping cough. All vaccines used in Australia undergo stringent testing and ongoing monitoring.
Researchers have developed the first National Healthy Skin Guideline to address record rates of skin infections in Australia’s Indigenous communities.
Aboriginal mum and child
Thousands of children born in Papua New Guinea (PNG) no longer face a future cut short by severe pneumonia, thanks to the introduction of pneumococcal vaccination as part of the country’s National Immunisation Program.
The Kids Research Institute Australia researchers will lead a new national clinical trial (COSI-2) to determine whether topical coconut oil can reduce late onset sepsis in extremely preterm infants.
World-first immunisations providing protection against deadly respiratory syncytial virus (RSV) could be just months away thanks to global research efforts spanning multiple decades.
Research teams led by The Kids Research Institute Australia have been awarded $3.75 million to support two innovative projects – one focused on pioneering a national ‘Food Atlas’ to map access to healthy and unhealthy food across the country, and the other on developing new ways to prevent Strep throat and rheuma
Invasive Group B Streptococcus remains a leading cause of infant morbidity and mortality. Intrapartum antibiotic prophylaxis has been implemented in many countries with a reduction in early-onset disease, but an effective vaccine may further reduce the disease burden. Candidate vaccines targeting capsular polysaccharides and surface proteins are now in clinical trials.
The incidence of respiratory syncytial virus (RSV) in adults is inadequately defined and the impact of SARS-CoV-2-related non-pharmaceutical interventions (NPIs) is underexplored. Using laboratory data, we described the detection rate of RSV in adults ≥16 years in Western Australia (WA) between 2017 and 2023.